Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06324396 · ClinicalTrials.gov registry record · Phase 1

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

A Phase 1 study of Fontan Circulation, sponsored by Children's Mercy Hospital Kansas City.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT06324396 is a Phase 1 study of Fontan Circulation that is actively recruiting participants, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06324396, a Phase 1 study of Fontan Circulation, is actively recruiting participants, sponsored by Children's Mercy Hospital Kansas City.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation.

Conditions Studied

Interventions

  • DRUG Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg)
  • DRUG Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)

Study Locations (1)

Missouri

  • Children's Mercy Hospital - Kansas City

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-03-01
Est. Completion 2026-12-31
Phase Phase 1

What the Registry Record Tells You About NCT06324396

The ClinicalTrials.gov registry entry for NCT06324396 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fontan Circulation appearing as the primary indexed condition, and to 2 interventions - of which Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg) is the first listed.

NCT06324396 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT06324396 about?

NCT06324396 is a clinical study titled "IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease". This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation.

What is the current status of trial NCT06324396?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-03-01. Estimated completion is 2026-12-31.

What conditions does trial NCT06324396 study?

This clinical trial studies the following conditions: Fontan Circulation.

What interventions are being tested in trial NCT06324396?

The interventions under investigation include: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg) (DRUG), Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years) (DRUG).

Who is sponsoring clinical trial NCT06324396?

This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06324396 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fontan Circulation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.